Argus Research maintains Herbalife at Buy, raises price target to $20 from $15
Argus Research kept its Buy rating on Herbalife and increased its price target to $20 from $15, suggesting a 28.3% upside from the Nov 10 close of $15.59.
How this was made

The 30-second read
Why it matters
A higher price target can influence short-term positioning, but without new disclosures it is unlikely to drive a sustained repricing.
Market read
This is a single-name bullish analyst update with a stated upside implication versus the Nov 10 close.
What to watch
Traders may discount PT changes if they are not accompanied by new earnings estimates, margin outlook revisions, or fresh guidance.
Background
The piece is an analyst note update from Argus Research on Herbalife.
Ticker impact
Argus maintained Herbalife at Buy and raised its price target to $20 from $15, implying upside versus the Nov 10 close.
Likely mild upward bias as traders price in the higher analyst target, with follow-through depending on broader earnings/guidance expectations.
The article provides only an analyst rating and price-target change, with no new company-specific operational or financial disclosure.
Market effects
Minimal, since this is a single-name analyst target change with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
The raised target may reflect valuation assumptions rather than new fundamentals, so price may not follow if upcoming company results disappoint.
Key entities
- companyHerbalife
Subject of the analyst action: maintained Buy and raised price target to $20 from $15.





